Tue.Sep 17, 2024

article thumbnail

FDA clears sleep apnoea feature for new Apple Watch

pharmaphorum

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with the launch of its new operating system for the wearable.The Breathing Disturbances function is part of watchOS 11, which makes its debut today alongside the release of the latest Apple Watch Series 10 which was revealed at the company's new product reveal earlier this month and is due to become available on 20th September.

article thumbnail

Ascendis trial data piles pressure on BioMarin

Bio Pharma Dive

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.

Trials 279
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists Discover a Brain Network Twice The Size in Depression Patients

AuroBlog - Aurous Healthcare Clinical Trials blog

(Andrew Brookes/Connect Images/Getty Images) The more we know about how depression takes hold in the brain, the better we can prevent and treat it, and new research has identified a brain network that seems to be twice its typical size in most people with depression.

Scientist 186
article thumbnail

ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial

Bio Pharma Dive

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

Pharmaceutical Technology

Poseida Therapeutics has received RMAT designation from the US FDA for its CAR-T cell therapy, P-BCMA-ALLO1.

241
241
article thumbnail

Nura Bio gets another $68M, new CEO to advance ‘neuroprotective’ brain drugs

Bio Pharma Dive

The funding will support mid-stage testing of a drug the company believes to have the potential to treat a range of neurodegenerative conditions.

Drugs 301

More Trending

article thumbnail

‘Really exciting times’: One biotech’s view of radiopharma’s boom

Bio Pharma Dive

Backed by Bristol Myers Squibb, Ratio Therapeutics has a front row seat to the pharmaceutical industry’s pivot into the field of targeted radiation drugs.

Drugs 144
article thumbnail

FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor  

Pharmaceutical Technology

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed sepsis.

147
147
article thumbnail

Express Scripts sues FTC over report critical of PBM business practices

Bio Pharma Dive

The pharmacy benefit manager said its lawsuit is necessary to protect against misinformation about the industry, while the FTC promised to defend its research.

Pharmacy 130
article thumbnail

MaxCyte and Kamau Therapeutics sign platform license agreement

Pharmaceutical Technology

MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.

Licensing 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer

Fierce Pharma

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.

article thumbnail

Equillium collaborates with Vivtex for oral formulation of autoimmune therapy

Pharmaceutical Technology

The partnership will see AI-enabled screening used to address bioavailability issues with Equillium’s cytokine-targeting peptide.

article thumbnail

CDMO Serán snags $200M Bain-led investment to build its first commercial facility

Fierce Pharma

With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its cust | With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its customers.

article thumbnail

SBTi approves Piramal Pharma’s GHG reduction targets

Pharmaceutical Technology

The SBTi has validated and approved India's Piramal Pharma’s near-term greenhouse gas (GHG) emission reduction targets.

130
130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

F2G raises $100 million to combat innovation 'paucity in antifungals

Outsourcing Pharma

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.

Marketing 111
article thumbnail

Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants

Pharmaceutical Technology

Sanofi has commenced the shipping of BEYFORTUS to the US for healthcare providers and the Vaccines for Children programme.

article thumbnail

J&J talc appeal upends $260M award to Oregon woman with mesothelioma

Fierce Pharma

Three months after a jury awarded $260 million to an Oregon woman who claimed | Three months after a jury awarded $260 million to an Oregon woman who claimed that her use of Johnson’s Baby Powder caused her to develop mesothelioma, a state judge has overturned the verdict and granted the company a new trial.

Trials 91
article thumbnail

Express Scripts sues FTC and demands drug pricing report retraction

Pharmaceutical Technology

The company claims that the FTC’s July 2024 report is riddled with “false and misleading claims” about the PBM industry.

Drugs 130
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

FDA designations boost AI-Driven cell therapy approach for Duchenne muscular dystrophy

BioPharma Reporter

The FDA has granted Orphan Drug and Rare Pediatric Disease Designations to Somiteâs cell replacement therapy for the treatment of Duchenne muscular dystrophy.

Drugs 116
article thumbnail

Podcast: How drones are transforming the clinical supply chain in Africa

Pharmaceutical Technology

Drones are starting to play a vital role in the clinical supply chain across sub-Saharan Africa to reach more patients.

article thumbnail

uMotif expands site and patient platform with ClinOne acquisition

Outsourcing Pharma

uMotif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its platform with the acquisition of ClinOne, a provider of site platform solutions.

article thumbnail

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

Pharmaceutical Technology

Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.

130
130
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Eli Lilly's eczema drug receives FDA approval one year after its initial rejection

BioPharma Reporter

The original concerns of the US regulatory agency over the manufacturing of Eli Lillyâs Ebglyss seem to have been resolved, as the FDA greenlit the antibody drug on Friday.

article thumbnail

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

Pharmaceutical Technology

BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.

article thumbnail

Trial sets up filings for Boehringer IPF drug nerandolimast

pharmaphorum

Boehringer will file its idiopathic pulmonary fibrosis drug nerandolimast next year, a successor to its blockbuster Ofev, after a phase 3 win

Drugs 109
article thumbnail

Meet the Researcher: Liam Tremble

Drug Discovery World

DDW’s Megan Thomas looks at a day in the life of Liam Tremble, Principal Scientist at Poolbeg Pharma. 1. Where do you work, and can you tell us what you’re working on at the moment?  I work at Poolbeg Pharma, where we are developing novel treatments for diseases with unmet medical needs and large addressable markets, with programmes in oncology, infectious diseases and endocrinology.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

After FDA no, MSD/Daiichi post new data with lung cancer ADC

pharmaphorum

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line treatment with EGFR inhibitors.The HERTHENA-Lung02 study in EGFR-mutated non-small cell lung cancer (NSCLC), involving patients with locally advanced or metastatic disease previously treated with EGFR drugs, revealed a significant improvement in progression-free survival (PFS) compared to a chemotherapy regimen.

Drugs 96
article thumbnail

UKRI’s MRC awards £27.4m to University of Dundee research unit

Pharma Times

The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension

Research 113
article thumbnail

Mitigating diagnostic errors in clinical trial participants: The role of drug safety/pharmacovigilance

pharmaphorum

Mitigating diagnostic errors in clinical trial participants: The role of drug safety/pharmacovigilance Mike.

article thumbnail

Coherus' cancer biosimilar faces supply squeeze after company's contract manufacturer overextends itself

Fierce Pharma

Nearly a year after Coherus BioSciences’ on-body injector for Udenyca was rejected over external production issues, a third-party manufacturer has caused another spot of bother for the Ca | Thanks to “over-commitments and capacity constraints” facing the U.S.-based contractor in charge of final packaging for Coherus' Udenyca, the copycat cancer med will suffer a “temporary” supply interruption, the company said last week.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.